Comparison of PACE clinical trial versus real-world (RW) ponatinib (PON) prescribing and duration of therapy (DOT) in US chronic-phase chronic myeloid leukemia (CP-CML) patients (pts).

e18540Background: PON demonstrated efficacy in pts with highly-resistant CP-CML in the pivotal PACE trial. Introduced to the US market in Dec’12, PON was reintroduced in Jan’14 after an 11-wk withd...